title: Selective expression of a splice variant of decay-accelerating factor in c-erbB-2-positive mammary carcinoma cells showing increased transendothelial invasiveness.
abstract: By differential-display-PCR a subclone of the SK-BR-3 cell line with high in vitro transendothelial invasiveness was identified to express increased levels of a new alternative splice variant of decay-accelerating factor (DAF). DAF seems to play an important role in some malignant tumours since on the one hand the expression of complement inhibitors on the surface of tumour cells prevents the accumulation of complement factors and in consequence cell lysis. On the other hand, DAF has been identified as a ligand for the CD97 surface receptor which induces cell migration. Immunofluorescence procedures, Western blot analyses, and cDNA clone sequencing were employed to confirm the expression of DAF restricted to invasive tumour cells. Using a radioactive RNA-in situ hybridisation on freshly frozen tissue microarrays and RT-PCR on native tumour tissue, the expression of alternative spliced DAF mRNA was demonstrated in invasive breast cancer. Due to the fact that it could thereby not be detected in normal mammary tissues, it has to be confirmed in larger studies that the DAF splice variant might be a specific tumour marker for invasive breast cancer.
authors.affiliation: Institute of Clinical Chemistry and Laboratory Medicine, University of Muenster, Germany. brandt@uni-muenster.de
authors.forename: Burkhard
authors.initials: B
authors.lastname: Brandt
authors.forename: Jan-Hendrik
authors.initials: JH
authors.lastname: Mikesch
authors.forename: Ronald
authors.initials: R
authors.lastname: Simon
authors.forename: Antje
authors.initials: A
authors.lastname: Rötger
authors.forename: Dirk
authors.initials: D
authors.lastname: Kemming
authors.forename: Katrin
authors.initials: K
authors.lastname: Schier
authors.forename: Guido
authors.initials: G
authors.lastname: Sauter
authors.forename: Horst
authors.initials: H
authors.lastname: Bürger
mesh_terms: D017398:Alternative Splicing; D015703:Antigens, CD; D001483:Base Sequence; D014408:Biomarkers, Tumor; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000378:metabolism*; D018958:CD55 Antigens / Q000096:biosynthesis* / Q000737:chemistry*; D002465:Cell Movement; D003001:Cloning, Molecular; D003169:Complement Inactivator Proteins / Q000737:chemistry; D003165:Complement System Proteins / Q000378:metabolism; D018076:DNA, Complementary / Q000378:metabolism; D004587:Electrophoresis, Agar Gel; D004730:Endothelium, Vascular / Q000166:cytology; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D008024:Ligands; D008562:Membrane Glycoproteins / Q000096:biosynthesis; D008856:Microscopy, Fluorescence; D008969:Molecular Sequence Data; D009361:Neoplasm Invasiveness; D020411:Oligonucleotide Array Sequence Analysis; D016133:Polymerase Chain Reaction; D012313:RNA / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis* / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; D018958:CD55 Antigens; D003169:Complement Inactivator Proteins; D003165:Complement System Proteins; D018076:DNA, Complementary; D008024:Ligands; D008562:Membrane Glycoproteins; D012313:RNA; D012333:RNA, Messenger; D018719:Erb-b2 Receptor Tyrosine Kinases; D043562:Receptors, G-Protein-Coupled; C095004:ADGRE5 protein, human